SAB Biotherapeutics (NASDAQ:SABS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of SAB Biotherapeutics (NASDAQ:SABS) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

SABS has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SAB Biotherapeutics in a research note on Monday, November 17th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, November 17th. Leerink Partnrs upgraded SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. Finally, Leerink Partners initiated coverage on shares of SAB Biotherapeutics in a report on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $9.33.

SAB Biotherapeutics Stock Up 1.8%

Shares of SABS opened at $4.02 on Friday. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $2.80 and a 200 day moving average of $2.33. The company has a market cap of $191.39 million, a PE ratio of -1.30 and a beta of 0.60. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. On average, sell-side analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

Several institutional investors have recently made changes to their positions in SABS. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics in the third quarter worth about $30,000. Dimensional Fund Advisors LP bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at about $32,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth approximately $40,000. HB Wealth Management LLC lifted its position in shares of SAB Biotherapeutics by 10.9% in the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after purchasing an additional 25,800 shares during the period. Finally, Woodline Partners LP bought a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $5,730,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.